Latanoprost Stada (Latanoprost)

Latanoprost activates prostaglandin F (FP) receptors in the eye, which remodels the extracellular matrix of the ciliary body and increases uveoscleral outflow of aqueous humor. This enhanced drainage reduces intra‑ocular pressure, the key factor in glaucoma progression.

The dosing regimen for Latanoprost Stada is determined by the prescribing clinician. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact dose and timing should follow the prescriber’s instructions.

Safety data for latanoprost in pregnancy and lactation are limited. It is classified as pregnancy category unknown, so it should only be used if the potential benefit justifies the potential risk. Breastfeeding mothers should discuss risks with their healthcare provider.

To request Latanoprost Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Latanoprost belongs to the prostaglandin analog class, which generally offers once‑daily dosing and strong intra‑ocular pressure reduction. Compared with beta‑blocker or carbonic anhydrase inhibitor drops, prostaglandin analogs often have a more favorable dosing convenience and comparable efficacy, though side‑effect profiles differ.

Latanoprost Stada should be stored at room temperature, below 25 °C, in its original container. Protect the bottle from light and moisture, and keep it out of reach of children. Do not freeze the product.

Latanoprost Stada is applied as a sterile eye‑drop solution. The patient should wash hands, tilt the head back, pull down the lower eyelid to form a pocket, and place one drop into the conjunctival sac. Close the eye gently and avoid blinking excessively for a few seconds.

Serious risks, though rare, include severe allergic reactions, uveitis, corneal or macular edema, and paradoxical increases in intra‑ocular pressure. Patients should seek immediate medical attention if they experience sudden pain, vision loss, redness, or signs of infection.

Latanoprost Stada is contraindicated in individuals with active ocular infections, inflammation, or hypersensitivity to latanoprost or any component of the formulation. Patients with a history of severe ocular inflammation should discuss alternatives with their eye‑care professional.